ライフサイエンスコーパス: subcutaneous fat

1 ody mass index, total body fat, or abdominal subcutaneous fat.

2 ge enzymes/proteins in omental and abdominal subcutaneous fat.

3 ations among discrimination and visceral and subcutaneous fat.

4 nsidered important and valid measurements of subcutaneous fat.

5 icantly increased their total, visceral, and subcutaneous fat.

6 earch applications that consider measures of subcutaneous fat.

7 n the liver, intermuscular fat, or abdominal subcutaneous fat.

8 -specific recycling of circulating FFAs into subcutaneous fat.

9 gene in epididymal adipose tissue but not in subcutaneous fat.

10 alysis measurements of glycerol release from subcutaneous fat.

11 gher resistin mRNA levels in human abdominal subcutaneous fat.

12 lipolysis and lipogenesis in human abdominal subcutaneous fat.

13 factor-alpha (by 72%) and leptin (by 60%) in subcutaneous fat.

14 49653 in small arteries (n = 44) from human subcutaneous fat.

15 circulating, free base form of the drug into subcutaneous fat.

16 liver, lung, myocardium, skeletal muscle, or subcutaneous fat.

17 ross-sectional area, muscle attenuation, and subcutaneous fat.

18 tion favors more truncal and less peripheral subcutaneous fat.

19 oprotective and anti-inflammatory effects of subcutaneous fat.

20 etones, and sulfur-containing compounds than subcutaneous fat.

21 he connection between the nervous system and subcutaneous fat.

22 increased cardiometabolic risk compared with subcutaneous fat.

23 and mouse epididymal fat compared with their subcutaneous fat.

24 h and PTRF mRNA levels was observed in human subcutaneous fat.

25 l bone density, trabecular bone content, and subcutaneous fat.

26 se in visceral (intra-abdominal) compared to subcutaneous fat.

27 l cholesterol level, high glucose level, and subcutaneous fat.

28 , resulting in a higher ratio of visceral to subcutaneous fat (0.15 [0.02] vs 0.07 [0.01], p=0.002).

29 3 cm2 vs +3 cm2, respectively; P = .001) and subcutaneous fat (-13 cm2 vs +2 cm2, P = .003).

30 4-387), colostomy (5.07; 2.12-13.0), thicker subcutaneous fat (2.02; 1.33-3.21), and black race (0.35

31 ed weight (-2.9%) and BMI (-2.9%) in men and subcutaneous fat (-3.6% at L2-L3 and -4.7% at L4-L5), we

32 3] vs 1.99 [0.19]%, p=0.03), lower abdominal subcutaneous fat (460 [47] vs 626 [39] cm2, p=0.04), and

33 ver, respiratory motion and aberrations from subcutaneous fat affected the treatment but increasing t

34 Invasion beyond subcutaneous fat also predicted overall death (HR, 2.1 [

35 13.8%) abdominal fat: 1.5 +/- 0.2 kg (13.6%) subcutaneous fat and 0.9 +/- 0.1 kg (16.1%) visceral fat

36 with histologic examination of the skin and subcutaneous fat and evaluation of the skin during reduc

37 reated with antiretroviral agents often lose subcutaneous fat and have metabolic abnormalities, inclu

38 dwarfism, lordokyphosis, cataracts, loss of subcutaneous fat and impaired wound healing.

39 Abdominal and subcutaneous fat and increased liver weight account for

40 atrophy syndrome is characterized by loss of subcutaneous fat and is associated with increased restin

41 gest that SPARC expression is predominant in subcutaneous fat and its expression and secretion in adi

42 adiposity alleles are associated with higher subcutaneous fat and lower ectopic fat.

43 ft-tissue mass with infiltration of adjacent subcutaneous fat and minimal or no extension into the bo

44 esses weight loss, inadequate energy intake, subcutaneous fat and muscle loss, edema, and hand grip s

45 y fat, characterized by increased lower-body subcutaneous fat and reduced ectopic fat.

46 d by a layered closure of the ischioanal and subcutaneous fat and skin similar to the control interve

47 re racial differences in the distribution of subcutaneous fat and the length of the limbs relative to

48 were compared with total body fat, abdominal subcutaneous fat, and abdominal visceral fat in univaria

49 occur in higher numbers in visceral than in subcutaneous fat, and in female versus male mice.

50 the high fat-fed state, enhanced browning of subcutaneous fat, and increased adipose expression of GL

51 ction on DNL, liver fat, visceral fat (VAT), subcutaneous fat, and insulin kinetics in obese Latino a

52 erentiated histology, tumor extension beyond subcutaneous fat, and large caliber nerve invasion.

53 tional QTL influencing heat loss, percentage subcutaneous fat, and percentage heart was found for chr

54 EBCT-defined CAC scores, visceral and subcutaneous fat, and statin use were assessed in 2001 t

55 metabolic phenotype and the browning of the subcutaneous fat are impaired by the suppression of type

56 (109.5 cm2 vs. 152.9 cm2) but a higher mean subcutaneous fat area (287.8 cm2 vs. 214.6 cm2).

57 leptin levels were strongly associated with subcutaneous fat area (r = 0.760) but not with intra-abd

58 level of the umbilicus, total, visceral, and subcutaneous fat area (TFA [total fat area], VFA [viscer

59 The subcutaneous fat area at each site was calculated by sub

60 Subcutaneous fat area can be estimated well by linear me

61 ciated and predicted more of the variance in subcutaneous fat area than in intra-abdominal fat area.

62 ly with these variables (P < .001 except for subcutaneous fat area vs age [P = .003]).

63 Total subcutaneous fat area was calculated as the sum of these

64 Total subcutaneous fat area was defined as total fat area minu

65 ypertension, even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area,

66 hypertension even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area,

67 , when LIS and LIR subjects were matched for subcutaneous fat area, age, and gender, they had similar

68 ression model after adjustment for abdominal subcutaneous fat area, age, sex, 2-h plasma glucose leve

69 For subcutaneous fat area, all anthropometric indices were l

70 Higher visceral fat density, subcutaneous fat area, and muscle-to-fascia ratio were a

71 t for total subcutaneous fat area, abdominal subcutaneous fat area, body mass index, or waist circumf

72 For each 1-cm(2) decrease in abdominal subcutaneous fat area, leptin decreased by 0.044 ng/mL w

73 t for total subcutaneous fat area, abdominal subcutaneous fat area, or waist circumference; however,

74 10-11 years even after adjustment for total subcutaneous fat area, total fat area, BMI, or waist cir

75 fat area], VFA [visceral fat area], and SFA [subcutaneous fat area], respectively).

76 c studies and quantification of visceral and subcutaneous fat areas (VFA and SFA) using abdominal com

77 white ethnicity had intra-abdominal fat and subcutaneous fat areas measured as part of the Atheroscl

78 ometric indices with intra-abdominal fat and subcutaneous fat areas measured by magnetic resonance im

79 Intra-abdominal fat and subcutaneous fat areas were quantified by computed tomog

80 The visceral and subcutaneous fat areas were significantly reduced follow

81 und in visceral adipose tissue and abdominal subcutaneous fat areas.

82 amined nonadipocyte stromal cells from human subcutaneous fat as a novel source of therapeutic cells.

83 Abdominal visceral fat (AVF), abdominal subcutaneous fat (ASF), and abdominal total fat (ATF) we

84 ance (beta=0.08, P<0.05), whereas lower body subcutaneous fat associated with higher cardiac output (

85 2%) and at L4-L5 (men -22.4%, women -17.8%), subcutaneous fat at L2-L3 (men -15.7%, women -11.4%) and

86 l area of skeletal muscle, visceral fat, and subcutaneous fat at the level of the L3 vertebrae.

87 Body fat was determined by DXA, and subcutaneous fat at triceps, biceps, subscapular, suprai

88 rteriovenous difference across the abdominal subcutaneous fat bed in humans.

89 us dose of [1-(14)C]oleate followed by timed subcutaneous fat biopsies (abdominal and femoral) and th

90 ]palmitate followed by omental and abdominal subcutaneous fat biopsies to measure direct FFA storage.

91 Subcutaneous fat biopsies were obtained from the upper t

92 nd adipose triglyceride lipase expression in subcutaneous fat biopsies.

93 acers were intravenously infused followed by subcutaneous fat biopsies.

94 Adipocytes collected from subcutaneous fat biopsy samples after normal and restric

95 enes in a subset of subjects who underwent a subcutaneous fat biopsy.

96 These individuals also had higher subcutaneous fat but lower liver fat and a lower viscera

97 Abdominal subcutaneous fat, but not visceral fat, area was higher

98 pose stromal cells from omental fat, but not subcutaneous fat, can generate active cortisol from inac

99 formation (lipogenesis) were investigated in subcutaneous fat cells from 204 sedentary and 336 physic

100 itivity to insulin's antilipolytic effect in subcutaneous fat cells is selectively lower in sedentary

101 the significantly reduced H-Ras occurred in subcutaneous fat cells, while the reduced PI3K and PCNA

102 gene, PLIN2, expressed only by sebocytes and subcutaneous fat cells.

103 n SR: history of fascial dehiscence, thicker subcutaneous fat, colostomy, and white race.

104 inal fat mass, and increased extra-abdominal subcutaneous fat, compared with wild-type mice.

105 absorptiometry), and abdominal visceral and subcutaneous fat (computed tomography) were measured in

106 revented weight gain, decreased visceral and subcutaneous fat content (P < 0.03 and 0.01, respectivel

107 Subcutaneous fat correlated significantly with mean lept

108 to cortisone) and was higher in omental than subcutaneous fat (cortisone to cortisol, median 57.6 pmo

109 including male sex, older age, and decreased subcutaneous fat), CP is independently associated with s

110 Subcutaneous fat declined (-17.2%; P < 0.001), whereas t

111 ross tertiles, BMI and percentage of fat and subcutaneous fat decreased, while hepatic fat increased.

112 bone mineral density, visceral fat area, and subcutaneous fat density.

113 ed rats did have increased plasma leptin and subcutaneous fat deposition and markedly abnormal glucos

114 correlates with insulin resistance, whereas subcutaneous fat deposition correlates with circulating

115 Excessive non-subcutaneous fat deposition may impair the functions of

116 The overall burden of non-subcutaneous fat deposition, but not abdominal subcutane

117 BMI and WHR depends on the assumed model of subcutaneous fat deposition.

118 percentage of total fat tissue but had more subcutaneous-fat deposition than did the uninfected cont

119 ter [P = 0.38] and pterygoid [P = 0.70]) and subcutaneous fat deposits (neck [P = 0.44] and submental

120 hether an imbalance between the visceral and subcutaneous fat depots and a corresponding dysregulatio

121 cient mice had overall smaller adipocytes in subcutaneous fat depots but larger adipocytes in paramet

122 ptake into visceral and upper and lower body subcutaneous fat depots in 21 premenopausal women.

123 ed to the phenotype of high visceral and low subcutaneous fat depots in obese adolescents.

124 Intraabdominal and subcutaneous fat depots were two- to threefold greater i

125 We examined the role of visceral and subcutaneous fat depots, independent of BMI, on the dysl

126 Changes in body weight, visceral and subcutaneous fat depots, oral glucose tolerance, insulin

127 It is VAT, more than subcutaneous fat depots, which is particularly associate

128 us fat index with the standard scores of non-subcutaneous fat depots.

129 in microanatomy based on known properties of subcutaneous fat, dermis, and epidermis.

130 Gonadal fat develops postnatally, whereas subcutaneous fat develops between embryonic days 14 and

131 m-operated animals, whereas transplants with subcutaneous fat did not affect atherosclerosis despite

132 Measures of intraabdominal and subcutaneous fat did not predict fasting hyperinsulinemi

133 APCs derived from subcutaneous fat differentiate well in the presence of c

134 iety response and have altered abdominal and subcutaneous fat distribution, with Rai1(+/-) female mic

135 ease, myocardial infarction and visceral and subcutaneous fat distribution; however, the underlying p

136 se in rodents and humans, while expansion of subcutaneous fat does not carry the same risks.

137 ed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU.m(-2).

138 Increased visceral fat, rather than subcutaneous fat, during the onset of obesity is associa

139 Primary ASCs isolated from rat and human subcutaneous fat exhibited mechanical memory, demonstrat

140 lin sensitive, which correlated with massive subcutaneous fat expansion.

141 rkedly inhibited beige adipocyte function in subcutaneous fat following cold exposure or beta3-agonis

142 ting lungs, anisotropic skeletal muscle, and subcutaneous fat) forward models were compared with meas

143 of the defatted dry matter and marbling and subcutaneous fat fractions, were assessed on 86 ham samp

144 , from 43.1+/-4.5 kg/m2 to 32.3+/-4.0 kg/m2, subcutaneous fat from 649+/-162 cm2 to 442+/-127 cm2, VA

145 fat gain (rho=-0.42, p=0.004), but not with subcutaneous fat gain (rho=-0.22, p=0.15).

146 is was altered; Rosi-induced body weight and subcutaneous fat gain and liver lipid accumulation were

147 ry, liver, skeletal muscle, and visceral and subcutaneous, fat) gene-regulatory networks (GRNs) infer

148 trate that resident innate lymphoid cells in subcutaneous fat generate and activate beige adipocytes,

149 of visceral fat and relatively low abdominal subcutaneous fat have a phenotype reminiscent of partial

150 composition and energy stores in the form of subcutaneous fat have long-term effects on offspring BP

151 ratio of abdominal visceral fat to abdominal subcutaneous fat improved significantly more in the GHRH

152 direct FFA storage in abdominal and femoral subcutaneous fat in 10 and 11 adults, respectively, duri

153 e; 3) peripheral fat, associated with higher subcutaneous fat in abdominal and thigh regions; and 4)

154 fat distribution, ie, significant losses of subcutaneous fat in association with metabolic abnormali

155 of MRI to quantify fat content in flesh and subcutaneous fat in fish cutlets was investigated.

156 Discrimination was not associated with subcutaneous fat in minimally (P = 0.95) or fully adjust

157 egulated in human visceral fat compared with subcutaneous fat in obese individuals.

158 ting free fatty acids (FFAs) in visceral and subcutaneous fat in postabsorptive women.

159 rt, and perirenal fat volume; fat content in subcutaneous fat in the hip region in both sexes; fatty

160 eater gestational weight gain and accrual of subcutaneous fat in the mother but lower fetal growth co

161 rates were greater in omental than abdominal subcutaneous fat in women (1.2 +/- 0.8 vs. 0.7 +/- 0.4 m

162 asis after RYGB is associated with decreased subcutaneous fat, increased postprandial PYY, GLP-1, and

163 and CD8 T-cell infiltrates in the dermis and subcutaneous fat, increased serum immunoglobulin G2a lev

164 erence -0.05 (95% CI: -0.08, -0.02) SDS] and subcutaneous fat index [difference -0.06 (95% CI: -0.10,

165 fference 0.05 (95% CI: 0.02, 0.08) SDS], and subcutaneous fat index [difference 0.06 (95% CI: 0.02, 0

166 associated with a 1 SD increment in the non-subcutaneous fat index [odds ratio (OR): 1.41; 95% CI: 1

167 The relation between non-subcutaneous fat index and calcified coronary plaque rem

168 each depot separately, we also created a non-subcutaneous fat index with the standard scores of non-s

169 -ray absorptiometry, and organ fat including subcutaneous fat index, visceral fat index, pericardial

170 associations with reductions in visceral and subcutaneous fat, indicating that the drug may have an o

171 Transplantation of subcutaneous fat into mice with diet-induced obesity sho

172 for patients who had histologic evidence of subcutaneous fat involvement in comparison with patients

173 ss than 10g lipid per 100g after trimming of subcutaneous fat, irrespective of age.

174 We also found that SirT1 expression in human subcutaneous fat is inversely related to adipose tissue

175 shows that the short TCF7L2 mRNA variant in subcutaneous fat is regulated by weight loss and is asso

176 ascular endothelial cells (EC) from lung and subcutaneous fat is slow, like HDMEC, whereas internaliz

177 fraction occurs at the interface between the subcutaneous fat layer and the glandular parenchyma and

178 rapidly and have limited capacity to expand subcutaneous fat, leading to central fat storage and ect

179 aps in understanding serial changes in fetal subcutaneous fat, lean body mass, and organ volume in as

180 mical data on longitudinal measures of fetal subcutaneous fat, lean body mass, and organ volumes.

181 Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring th

182 s that include profound lymphopenia, loss of subcutaneous fat, lordokyphosis, and severe metabolic de

183 IV epidemic, lipodystrophy, characterized by subcutaneous fat loss (lipoatrophy), with or without cen

184 te the relation between leptin secretion and subcutaneous fat loss in HIV-infected patients.

185 gnificant reduction in leptin secretion with subcutaneous fat loss in this population.

186 ial Dunnigan lipodystrophy, characterized by subcutaneous fat loss, is frequently caused by an R482W

187 at least 2 of these indicators: weight loss, subcutaneous fat loss, muscle wasting, and inadequate en

188 ed waist circumference (11-13 cm), abdominal subcutaneous fat mass (1650-1850 cm(3)), visceral fat ma

189 ing for percent total body fat and abdominal subcutaneous fat mass (partial correlation r = -0.73, P

190 e phenotype, with a significant reduction in subcutaneous fat mass but not visceral fat mass.

191 android/gynoid ratio, and preperitoneal and subcutaneous fat mass by physical examinations, dual-ene

192 ssion, fat oxidation, energy expenditure and subcutaneous fat mass loss compared with male mice, impl

193 Subcutaneous fat mass was not associated with any respir

194 ing to measure accurately intraabdominal and subcutaneous fat masses in 14 obese [body mass index (BM

195 to the higher total fat and particularly the subcutaneous fat masses.

196 versus 20.8+/-2.4 kg, P>0.05) and abdominal subcutaneous fat-matched (230.6+/-24.9 versus 261.4+/-34

197 I) for assessment of whole body visceral and subcutaneous fat, maximal aerobic capacity test and musc

198 bcutaneous fat deposition, but not abdominal subcutaneous fat, may be a correlate of coronary atheros

199 six sites (240 soft-tissue, colonic gas, and subcutaneous fat measurements).

200 increased adipogenesis and/or lipogenesis in subcutaneous fat, mediated by the LPIN1 gene, may preven

201 During cold-induced 'browning' of subcutaneous fat, most 'beige' adipocytes stem from de n

202 y automated CT markers included visceral and subcutaneous fat, muscle, bone density, liver fat, all n

203 13, and 13a, decreased after weight loss in subcutaneous fat (n = 46) and liver (n = 11) and was mor

204 rse events were reported in the xenon group: subcutaneous fat necrosis and transient desaturation dur

205 -derived stromal cells (ASCs) from abdominal subcutaneous fat obtained from healthy normal-weight you

206 Visceral fat (omentum) and abdominal subcutaneous fat of 4 patients were also not infected wi

207 gth in leukocytes, skeletal muscle, skin and subcutaneous fat of 87 adults (aged 19-77 years).

208 y was to characterize ASCs isolated from the subcutaneous fat of domestic pigs (pASCs) and examine th

209 Cs) and whole-fat tissues from the abdominal subcutaneous fat of obese and nonobese subjects, we show

210 6) and liver (n = 11) and was more common in subcutaneous fat of subjects with type 2 diabetes than i

211 mals (P = 0.748) that was not due to reduced subcutaneous fat or LBM, but rather preferential loss of

212 ained after further adjustment for abdominal subcutaneous fat (OR: 1.40; 95% CI: 1.00, 1.94).

213 aging including sarcopenia, cataracts, less subcutaneous fat, organ shrinkage, and others.

214 her amount of total body fat (p < 0.001) and subcutaneous fat (p < 0.001) than those without NAFLD.

215 verage, 28% greater total fat and 30% higher subcutaneous fat (P <.001 for both), but 10% less parasp

216 In stepwise regression modeling, subcutaneous fat (P <0.0001), but not visceral fat, was

217 e uptake of meal FAs increased in upper-body subcutaneous fat (P = 0.028) in weight-reduced UOb women

218 cm or greater (P<.001), invasion beyond the subcutaneous fat (P<.003), multiple nerve involvement (P

219 ntly blunted angiogenic growth compared with subcutaneous fat (P<0.001) that was associated with mark

220 r predictors of the thickness of the deltoid subcutaneous fat pad (DSFP) than weight and gender and (

221 ) body-wide depot to distinguish it from the subcutaneous fat pads characteristic of the abdomen and

222 significantly elevated in the epididymal and subcutaneous fat pads from ob/ob mice compared with thei

223 ver, spleen, kidneys, bone marrow, skin, and subcutaneous fat pads from these mice showed no abnormal

224 ncreasing adiposity in the visceral, but not subcutaneous, fat pads of ob/ob mice.

225 erineural invasion, tumor invasion to/beyond subcutaneous fat, poor cellular differentiation, and tum

226 5% CI, 1.70-3.30), as was invasion to/beyond subcutaneous fat (PR, 2.37; 95% CI, 1.78-3.14).

227 Increased visceral rather than subcutaneous fat predicts endothelial dysfunction.

228 otal fat mass (r=0.323, P<0.05) or abdominal subcutaneous fat (r=0.27, P=0.05).

229 ge, 34.4%-54.9%) and significantly lower for subcutaneous fat (range, 10.3%-12.6%), compared with tha

230 Visceral and the visceral-to-subcutaneous fat ratio increased and insulin sensitivity

231 profile, including an increased visceral to subcutaneous fat ratio, insulin resistance, dyslipidemia

232 onoclonal gammopathy, a unique patterning of subcutaneous fat reticulation and hypodense bone marrow

233 h were associated with tumor invasion beyond subcutaneous fat (risk ratio, 9.1 [95% CI, 2.8-29.2] and

234 factors for metastasis were: invasion beyond subcutaneous fat (RR, 11.21; 95% CI, 3.59-34.97), Breslo

235 , 4.55; 95% CI, 1.41-14.69), invasion beyond subcutaneous fat (RR, 4.49; 95% CI, 2.05-9.82), and peri

236 , 9.64; 95% CI, 1.30-71.52), invasion beyond subcutaneous fat (RR, 7.61; 95% CI, 4.17-13.88), Breslow

237 slaughter, longissimus (muscle and meat) and subcutaneous fat samples from the offspring were collect

238 animal skin, carcass surface, fresh meat and subcutaneous fat samples) at a commercial abattoir, usin

239 The results suggest that, using subcutaneous fat samples, a portable NIRS could be used

240 mes by using the spectra from fresh meat and subcutaneous fat samples.

241 f miR-375 were found in VAT in comparison to subcutaneous fat (SAT).

242 tal body weight) and soft tissues (abdominal subcutaneous fat [SAT], adipose tissue, visceral adipose

243 index (Si) and intra-abdominal fat (IAF) and subcutaneous fat (SCF) areas.

244 Specifically, subcutaneous fat (SF), intra-abdominal fat (VF), externa

245 , as in control subjects, amounts of truncal subcutaneous fat showed a stronger correlation with gluc

246 Abdominal subcutaneous fat showed weaker associations with concent

247 rmula had greater accretion of visceral than subcutaneous fat, showed increased signs of macrophage i

248 orrelated positively with body-mass index in subcutaneous fat (Spearman correlation=0.51, p=0.006).

249 hydrate intake may have a stronger effect on subcutaneous fat storage than does dietary fat intake.

250 vealed a strong negative correlation between subcutaneous fat stores and dominance rank in the inters

251 lation; (ii) skinfold thickness, to estimate subcutaneous fat stores necessary to fuel growth and imm

252 ra (T1, 586 msec +/- 73; T2, 49 msec +/- 4), subcutaneous fat (T1, 382 msec +/- 13; T2, 68 msec +/- 4

253 d to higher triglycerides and more total and subcutaneous fat than darunavir/ritonavir.

254 ge of meal FAs in both upper- and lower-body subcutaneous fat than did the LOb and UOb women (P = 0.0

255 les having more leptin and greater levels of subcutaneous fat than males.

256 al fibrosis with greater preservation of the subcutaneous fat than wild-type mice.

257 In the dermis and subcutaneous fat, the EVE treated groups showed signific

258 For subcutaneous fat, the results were compared with vision

259 The abdominal fat area (AFA) and subcutaneous fat thickness (SFT) were measured using T1-

260 Exponential dose increases for increased subcutaneous fat thicknesses can be reduced substantiall

261 y was to quantify the anatomy of the muscle, subcutaneous fat, tibia, fibula and arteries in the lowe

262 no acute effect on WISP1 gene expression in subcutaneous fat tissue in overweight subjects who had u

263 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-rec

264 WISP1 expression in visceral and subcutaneous fat tissue was associated with markers of i

265 oth-root slices, which were filled with only subcutaneous fat tissue.

266 ly low expression in the gonads, gizzard and subcutaneous fat tissues of chickens.

267 We isolated MSCs from cardiac and subcutaneous fat tissues of mice with LVD 28 days after

268 how that HSF1 levels are higher in brown and subcutaneous fat tissues than in those in the visceral d

269 Simulations using several subcutaneous fat-to-dermis concentration ratios were per

270 Abdominal subcutaneous fat took up FFAs more avidly than femoral f

271 Subcutaneous fat transplantation also protects against c

272 nitiates adipogenesis after 4 weeks, whereas subcutaneous fat undergoes hypertrophy for a period of u

273 h versus low ratio of visceral to visceral + subcutaneous fat (VAT/[VAT+SAT]).

274 am13a knockout (KO) have a lower visceral to subcutaneous fat (VAT/SAT) ratio after high-fat diet cha

275 mented all noncerebral structures except for subcutaneous fat, visceral fat, and skeletal muscle, whi

276 Subcutaneous fat, visceral fat, paraspinous musculature,

277 ed of 13 abdominal organs, 20 bone segments, subcutaneous fat, visceral fat, psoas muscle, and skelet

278 vs. 52,321.87 +/- 5125.05 mm(3), p=0.01) and subcutaneous fat volume (10,599.89 +/- 3683.57 vs. -5224

279 mass index (BMI), visceral fat volume (VFV), subcutaneous fat volume (SFV), and total fat volume (TFV

280 Arm muscle and subcutaneous fat volumes were measured before and after

281 Subcutaneous fat was also significantly related to lepti

282 Subcutaneous fat was assessed on the basis of the averag

283 In contrast, lower body subcutaneous fat was associated with eccentric remodelin

284 In contrast, lower body subcutaneous fat was associated with higher LV end-diast

285 More subcutaneous fat was associated with longer OS (HR, 0.62

286 Human subcutaneous fat was cultured in vitro to promote blood

287 was accurately detected, acceptable if only subcutaneous fat was excluded, or unacceptable if any br

288 Visceral and subcutaneous fat was measured using T(2) (*)-IDEAL.

289 2) was associated with mortality but indexed subcutaneous fat was not.

290 Subcutaneous fat was positively associated with long-cha

291 -induced visceral adipose formation, whereas subcutaneous fat was reduced similarly in both groups.

292 , visceral adipose tissue, but not abdominal subcutaneous fat, was significantly associated with conc

293 NIRS measurements in the carcass surface and subcutaneous fat were able to correctly classify 75.9% a

294 Visceral and subcutaneous fat were assessed via computed tomography s

295 Body weight and subcutaneous fat were decreased after RYGB, compared wit

296 Liver fat, VAT, and subcutaneous fat were determined by magnetic resonance s

297 rol level, high glucose level, and abdominal subcutaneous fat were included in the obtained model.

298 d CP, male sex, increased age, and decreased subcutaneous fat were independently associated with sarc

299 ion, tumor diameter >/=2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative s

300 19 cm (95% CI: 0.02, 0.37) greater abdominal subcutaneous fat, whereas those with stable low BMI had